DO PHARMACEUTICAL COST CONTROL POLICIES EFFECTIVE IN REDUCING PHARMACEUTICAL EXPENDITURE AND VOLUME? A SYSTEMATIC REVIEW

Author(s)

Lee KS1, Hendrie D2, Sunderland B2, Moorin RE3
1Ministry of Health Malaysia, Selangor, Malaysia, 2Curtin University, Western Australia, Australia, 3Curtin University, Perth, Australia

OBJECTIVES:   To synthesise and compare methodologically the reported impacts of pharmaceutical cost control policies on drug utilisation, drug costs and public pharmaceutical expenditure. METHODS:  We search major databases MEDLINE (Ovid), EMBASE (Ovid), EconLit and Google Scholar for randomised controlled trials (RCTs), non-randomised controlled trials (CCTs), repeated measures (RM) studies, interrupted time series (ITS) analyses, and before-after (BA) studies from 1 January 1991 to 31 December 2012. Combination of keywords covering four themes were used; Pharmaceuticals and Insurances, Cost Containment Measures, Health Care Policies, and Outcome Measures. Outcomes included drug volume (number of prescribed drugs, number of dispensed drugs) and drug expenditure (total drug expenditure, drugs cost or price). Studies evidence level were graded according to the Scottish Intercollegiate Guidelines Network (SIGN) grading system. RESULTS:  We identified ITS and 7 BA, carried out in 15 different countries

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PHP45

Topic

Economic Evaluation, Health Policy & Regulatory

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies, Pricing Policy & Schemes

Disease

Multiple Diseases

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×